The function of LA1 is consistent with the effects of erlotinib and MEK inhibition on tumor cell cluster formation whereas cetuximab lacks inhibition in low EGFR-expressing breast cancer cells 39, 40 with a very low response rate in the randomized phase II clinical trial 41. Here, MAP2K7 is linked to breast carcinoma.